THALES
20.3.2024 09:01:32 CET | Business Wire | Press release
Thales today announced the release of the 2024 Thales Data Threat Report, its annual report on the latest data security threats, trends, and emerging topics based on a survey of nearly 3000 IT and security professionals in 18 countries across 37 industries. This year’s report found that 93% of IT professionals believe security threats are increasing in volume or severity, a significant rise from 47% last year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320217738/en/
©Thales
Threats continue to increase in volume and severity
The number of enterprises experiencing ransomware attacks surged by over 27% in the past year. Despite this escalating threat, less than half of organisations have a formal ransomware plan in place, with 8% resorting to paying the ransom demands.
Malware stands out as the fastest-growing threat of 2024, with 41% of enterprises witnessing a malware attack in the past year – closely followed by phishing and ransomware. Cloud assets, including SaaS applications, cloud-based storage, and cloud infrastructure management, remain the primary targets for such attacks.
The report shows that for a second year running, human error remains the leading cause of data breaches, with 31% of enterprises pinpointing this as the root cause.
These insights are drawn from the 2024 Thales Data Threat Report, conducted by 451 Research. The report sheds light on how businesses are adapting their data security strategies and practices in response to an evolving threat landscape.
Compliance is the key to data security
The research found that over two fifths (43%) of enterprises failed a compliance audit in the past twelve months – with the report highlighting a very clear correlation between compliance and data security.
Of those that had failed a compliance audit in the past twelve months, 31% had experienced a breach that very same year. This compares to just 3% of those who had passed compliance audits.
Operational complexity continues to cause data headaches
Fundamental understanding of what systems, applications, and data are at risk continue to lag due to changing regulatory and threat landscapes. Only a third (33%) of organisations are able to fully classify all of their data, with a worrying 16% stating that they classify very little or none of their data.
Operational complexity remains a barrier. While the number of respondents reporting five or more key management systems is down (53% versus 62% last year), the average number declined only slightly (from 5.6 to 5.4).
The reality of multicloud across services and changing global data privacy regulations means that data sovereignty is a leading priority for businesses, with 28% identifying mandatory external key management as the leading way to achieve sovereignty. 39% said that data residency would no longer be an issue provided that external encryption, key management, and separation of duties were implemented.
“Enterprises need to know exactly what they’re trying to protect. With global data privacy regulations continually changing, they need to have good visibility across their organization to stand any chance of staying compliant,” said Sebastien Cano, Senior Vice President at Thales Cloud Protection and Licensing.
“If there’s one key takeaway from this year’s study, it’s that compliance is key. In fact, companies that had a good hold over their compliance processes and passed all their audits were also less likely to suffer a breach. We’ll start to see more compliance and security functions coming together. This would be a huge positive step to strengthen cyber defenses and build trust with customers,” he added.
Emerging technology poses both threats and opportunities
Looking ahead, the report also explored which emerging technologies are top-of-mind for IT and security professionals, with 57% identifying Artificial Intelligence (AI) as a huge source of concern. This was closely followed by IoT (55%) and Post Quantum Cryptography (45%).
That said, enterprises are also looking at the opportunities that emerging technologies bring, with over a fifth (22%) planning to integrate Generative AI into their security products and services in the next 12 months, and a third (33%) planning to experiment integrating the technology.
For more information please join our webinar with S&P Global on April 16, 2024 hosted by Eric Hanselman, Chief Analyst and Justin Lam, Research Analyst.
About the 2024 Thales Global Data Threat Report
The 2024 Data Threat Report (DTR) analyzes how core security practices have changed in response to or in anticipation of changing threats. This report also offers perspectives on what organizations can do to leverage data assets to expand opportunities to make their businesses more agile and build trust with their customers. This research was based on a global survey of 2,961 respondents fielded via web survey with targeted populations for each country, aimed at professionals in security and IT management. In addition to criteria about level of knowledge on the general topic of the survey, the screening criteria for the survey excluded those respondents who indicated affiliation with organizations with annual revenue of less than US$100 million and with US$100 million-$250 million in Australia, Brazil, Canada, France, Germany, Hong Kong, India, Italy, Japan, Mexico, the Netherlands, New Zealand, South Korea, Singapore, Sweden, the United Arab Emirates, the United Kingdom and the United States of America.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.
Thales has 81,000* employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.
* These figures exclude the ground transportation business, which is being divested
PLEASE VISIT
Cloud Protection & Licensing Solutions | Thales Group
Cybersecurity Solutions | Thales Group
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240320217738/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
